Correlation between plasma, intracellular, and cervical tissue levels of raltegravir at steady-state dosing in healthy women

Caroline Mitchell, Emily Roemer, Evangelyn Nkwopara, Brian Robbins, Theodore Cory, Tessa Rue, Courtney V Fletcher, Lisa Frenkel

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Raltegravir is an antiretroviral with potential value for preexposure prophylaxis (PrEP) against HIV, but the intracellular pharmacokinetics in genital tissue have not been described. In this study, healthy, HIV-uninfected nonpregnant women took 400 mg of raltegravir twice daily for 22 days. On day 8, 15, and 22, blood was collected 0, 4, 6, 8, and 12 h and cervical biopsy specimens taken 0, 6, and 12 h after raltegravir dosing. Plasma and intracellular raltegravir concentrations in peripheral blood mononuclear cells (PBMC) and cervical tissue were measured by tandem mass spectrometry. Linear mixed effects models evaluated correlations between different sample types, as well as differences in concentration between phases of the menstrual cycle. Ten women were enrolled: 9 completed all three visits and 1 completed two visits. The age (mean±standard deviation) of participants was 30±8 years. Trough plasma concentrations of raltegravir 12 h after a directly observed dose were above the HIV 95% inhibitory concentration (IC95) of 33 nM (14.6 ng/ml) in 96% of measurements, compared to 67% of PBMC and 89% of cervical tissue trough values. Across all measurements, only 2% (3/135) of plasma values fell below the IC95, compared to 10% (13/135) for PBMC and 6% (5/81) for cervical tissue. There was no impact of menstrual phase on raltegravir concentrations. In conclusion, cervical tissue raltegravir concentrations were no greater than plasma concentrations, and̃10% of all cervical tissue trough values were below the IC95, making the current twice-daily formulation of raltegravir impractical for PrEP.

Original languageEnglish (US)
Pages (from-to)3360-3365
Number of pages6
JournalAntimicrobial Agents and Chemotherapy
Volume58
Issue number6
DOIs
StatePublished - Jun 2014

Fingerprint

Blood Cells
HIV
Raltegravir Potassium
Menstrual Cycle
Tandem Mass Spectrometry
Pharmacokinetics
Biopsy

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Correlation between plasma, intracellular, and cervical tissue levels of raltegravir at steady-state dosing in healthy women. / Mitchell, Caroline; Roemer, Emily; Nkwopara, Evangelyn; Robbins, Brian; Cory, Theodore; Rue, Tessa; Fletcher, Courtney V; Frenkel, Lisa.

In: Antimicrobial Agents and Chemotherapy, Vol. 58, No. 6, 06.2014, p. 3360-3365.

Research output: Contribution to journalArticle

Mitchell, Caroline ; Roemer, Emily ; Nkwopara, Evangelyn ; Robbins, Brian ; Cory, Theodore ; Rue, Tessa ; Fletcher, Courtney V ; Frenkel, Lisa. / Correlation between plasma, intracellular, and cervical tissue levels of raltegravir at steady-state dosing in healthy women. In: Antimicrobial Agents and Chemotherapy. 2014 ; Vol. 58, No. 6. pp. 3360-3365.
@article{7f1f16167f2b46afa2a814bbc457df08,
title = "Correlation between plasma, intracellular, and cervical tissue levels of raltegravir at steady-state dosing in healthy women",
abstract = "Raltegravir is an antiretroviral with potential value for preexposure prophylaxis (PrEP) against HIV, but the intracellular pharmacokinetics in genital tissue have not been described. In this study, healthy, HIV-uninfected nonpregnant women took 400 mg of raltegravir twice daily for 22 days. On day 8, 15, and 22, blood was collected 0, 4, 6, 8, and 12 h and cervical biopsy specimens taken 0, 6, and 12 h after raltegravir dosing. Plasma and intracellular raltegravir concentrations in peripheral blood mononuclear cells (PBMC) and cervical tissue were measured by tandem mass spectrometry. Linear mixed effects models evaluated correlations between different sample types, as well as differences in concentration between phases of the menstrual cycle. Ten women were enrolled: 9 completed all three visits and 1 completed two visits. The age (mean±standard deviation) of participants was 30±8 years. Trough plasma concentrations of raltegravir 12 h after a directly observed dose were above the HIV 95{\%} inhibitory concentration (IC95) of 33 nM (14.6 ng/ml) in 96{\%} of measurements, compared to 67{\%} of PBMC and 89{\%} of cervical tissue trough values. Across all measurements, only 2{\%} (3/135) of plasma values fell below the IC95, compared to 10{\%} (13/135) for PBMC and 6{\%} (5/81) for cervical tissue. There was no impact of menstrual phase on raltegravir concentrations. In conclusion, cervical tissue raltegravir concentrations were no greater than plasma concentrations, and̃10{\%} of all cervical tissue trough values were below the IC95, making the current twice-daily formulation of raltegravir impractical for PrEP.",
author = "Caroline Mitchell and Emily Roemer and Evangelyn Nkwopara and Brian Robbins and Theodore Cory and Tessa Rue and Fletcher, {Courtney V} and Lisa Frenkel",
year = "2014",
month = "6",
doi = "10.1128/AAC.02757-13",
language = "English (US)",
volume = "58",
pages = "3360--3365",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "6",

}

TY - JOUR

T1 - Correlation between plasma, intracellular, and cervical tissue levels of raltegravir at steady-state dosing in healthy women

AU - Mitchell, Caroline

AU - Roemer, Emily

AU - Nkwopara, Evangelyn

AU - Robbins, Brian

AU - Cory, Theodore

AU - Rue, Tessa

AU - Fletcher, Courtney V

AU - Frenkel, Lisa

PY - 2014/6

Y1 - 2014/6

N2 - Raltegravir is an antiretroviral with potential value for preexposure prophylaxis (PrEP) against HIV, but the intracellular pharmacokinetics in genital tissue have not been described. In this study, healthy, HIV-uninfected nonpregnant women took 400 mg of raltegravir twice daily for 22 days. On day 8, 15, and 22, blood was collected 0, 4, 6, 8, and 12 h and cervical biopsy specimens taken 0, 6, and 12 h after raltegravir dosing. Plasma and intracellular raltegravir concentrations in peripheral blood mononuclear cells (PBMC) and cervical tissue were measured by tandem mass spectrometry. Linear mixed effects models evaluated correlations between different sample types, as well as differences in concentration between phases of the menstrual cycle. Ten women were enrolled: 9 completed all three visits and 1 completed two visits. The age (mean±standard deviation) of participants was 30±8 years. Trough plasma concentrations of raltegravir 12 h after a directly observed dose were above the HIV 95% inhibitory concentration (IC95) of 33 nM (14.6 ng/ml) in 96% of measurements, compared to 67% of PBMC and 89% of cervical tissue trough values. Across all measurements, only 2% (3/135) of plasma values fell below the IC95, compared to 10% (13/135) for PBMC and 6% (5/81) for cervical tissue. There was no impact of menstrual phase on raltegravir concentrations. In conclusion, cervical tissue raltegravir concentrations were no greater than plasma concentrations, and̃10% of all cervical tissue trough values were below the IC95, making the current twice-daily formulation of raltegravir impractical for PrEP.

AB - Raltegravir is an antiretroviral with potential value for preexposure prophylaxis (PrEP) against HIV, but the intracellular pharmacokinetics in genital tissue have not been described. In this study, healthy, HIV-uninfected nonpregnant women took 400 mg of raltegravir twice daily for 22 days. On day 8, 15, and 22, blood was collected 0, 4, 6, 8, and 12 h and cervical biopsy specimens taken 0, 6, and 12 h after raltegravir dosing. Plasma and intracellular raltegravir concentrations in peripheral blood mononuclear cells (PBMC) and cervical tissue were measured by tandem mass spectrometry. Linear mixed effects models evaluated correlations between different sample types, as well as differences in concentration between phases of the menstrual cycle. Ten women were enrolled: 9 completed all three visits and 1 completed two visits. The age (mean±standard deviation) of participants was 30±8 years. Trough plasma concentrations of raltegravir 12 h after a directly observed dose were above the HIV 95% inhibitory concentration (IC95) of 33 nM (14.6 ng/ml) in 96% of measurements, compared to 67% of PBMC and 89% of cervical tissue trough values. Across all measurements, only 2% (3/135) of plasma values fell below the IC95, compared to 10% (13/135) for PBMC and 6% (5/81) for cervical tissue. There was no impact of menstrual phase on raltegravir concentrations. In conclusion, cervical tissue raltegravir concentrations were no greater than plasma concentrations, and̃10% of all cervical tissue trough values were below the IC95, making the current twice-daily formulation of raltegravir impractical for PrEP.

UR - http://www.scopus.com/inward/record.url?scp=84901260730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901260730&partnerID=8YFLogxK

U2 - 10.1128/AAC.02757-13

DO - 10.1128/AAC.02757-13

M3 - Article

C2 - 24687503

AN - SCOPUS:84901260730

VL - 58

SP - 3360

EP - 3365

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 6

ER -